Clinical trials: Squamous-cell Non-Small-cell Lung Cancer
Advanced Squamous Non-Small Cell Lung Carcinoma
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1…
- Trial name
- NCT05127590
- Testing
- RBN-2397
- Where
- 19 sites in United States, Israel and 2 more
- Volunteers
- 50 people
- Sponsor
- Ribon Therapeutics, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Metastatic Solid Tumor, Advanced Solid Tumor
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents.
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
- Trial name
- NCT06561685
- Testing
- LY4050784, Pembrolizumab, Cisplatin
- Where
- 32 sites in United States, France and 4 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)
This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy.
- Trial name
- MERIT (NCT02774278)
- Testing
- Erlotinib
- Where
- 29 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 264 people
- Sponsor
- Hoffmann-La Roche
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of sirolimus and gold sodium thiomalate when given together in treating patients with advanced squamous non-small cell lung cancer (NSCLC).
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT01383668
- Testing
- sirolimus, gold sodium thiomalate, pharmacological study
- Sponsor
- Mayo Clinic
Metastatic Non-squamous Non Small Cell Lung Cancer
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
This is a randomized, open-label, multicenter, phase II study to compare a triplet combination of CBP501, pemetrexed and cisplatin with pemetrexed/cisplatin when administered to patients with locally advanced (stage IIIB with…
- Trial name
- CBP08-02 (NCT00942825)
- Testing
- CBP501 + Cisplatin + Pemetrexed, Cisplatin + Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 195 people
- Sponsor
- CanBas Co. Ltd.
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
The purpose of this study was to evaluate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162 in advanced NSCLC patients carrying specific molecular alterations.
- Trial name
- NCT02276027
- Testing
- BYL719, INC280, LDK378
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy…
- Trial name
- NCT06158958
- Testing
- ABBV-303, Budigalimab
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 27 people
- Sponsor
- AbbVie
Lung Cancer
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
In this single-arm, phase II study, we aimed to evaluate the efficacy and safety of sac-TMT plus bevacizumab in patients with advanced non-squamous NSCLC who showed disease progression on or after first-line ICI plus…
- Trial name
- NCT07244926
- Testing
- Sacituzumab tirumotecan plus bevacizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Carcinoma, Non-Small-Cell Lung
MYLUNG Consortium Part 3: Observational Study
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced…
- Trial name
- MYLUNG (NCT05885698)
- Where
- 17 sites in United States
- Volunteers
- 7,500 people
- Sponsor
- US Oncology Research
Lung Cancer
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00547443
- Testing
- carboplatin, paclitaxel, sorafenib tosylate
- Where
- 2 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006116
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 21 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Carcinoma, Squamous Cell
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Primary objective: To assess the response rate to induction therapy with docetaxel/CDDP. Secondary objectives: To assess Resectability after induction therapy Time to progression Overall survival Safety profile Quality of Life
- Trial name
- NCT00432315
- Testing
- Docetaxel + CDDP
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Sanofi
Renal Cell Carcinoma, Colorectal Adenocarcinoma
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Angiogenesis, the development of new blood vessels, plays an important role in the disease development and tumor growth in many solid organ malignancies.
- Conditions
- Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma
- Trial name
- NCT02835833
- Testing
- Nintedanib, Bevacizumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
Non-small Cell Lung Cancer
A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This is a multicenter, multinational, double-blind, 1:1 randomized, parallel-group, equivalence Phase 3 study to compare the efficacy and safety of MB02 plus chemotherapy (carboplatin and paclitaxel) versus Avastin® plus…
- Trial name
- STELLA (NCT03296163)
- Testing
- MB02 (Bevacizumab Biosimilar Drug), EU-approved Avastin®, Carboplatin
- Where
- 118 sites in Brazil, Bulgaria and 16 more
- Volunteers
- 627 people
- Sponsor
- mAbxience Research S.L.
Non-Squamous Non-Small Cell Lung Cancer
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily.
- Trial name
- NCT01066884
- Testing
- erlotinib [Tarceva]
- Where
- 2 sites in Russia
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Carcinoma, Non-Small-Cell Lung
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC
The purpose of this study is to compare the curative effect of oral S-1 with Pemetrexed in the maintenance treatment of advanced non-squamous non-small cell lung cancer (NSCLC), and initial to explore a new treatment strategy for…
- Trial name
- NCT03700333
- Testing
- S-1 therapy, Pemetrexed therapy
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-small-cell Lung Cancer
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
The primary objective of this study is to determine if the combination regimen of ARQ 197 with erlotinib will improve overall survival (OS) compared to erlotinib monotherapy in subjects with locally advanced or metastatic…
- Trial name
- ATTENTION (NCT01377376)
- Testing
- ARQ 197 and Erlotinib
- Where
- Japan
- Sponsor
- Kyowa Kirin Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.